JP2013528394A5 - - Google Patents

Download PDF

Info

Publication number
JP2013528394A5
JP2013528394A5 JP2013514792A JP2013514792A JP2013528394A5 JP 2013528394 A5 JP2013528394 A5 JP 2013528394A5 JP 2013514792 A JP2013514792 A JP 2013514792A JP 2013514792 A JP2013514792 A JP 2013514792A JP 2013528394 A5 JP2013528394 A5 JP 2013528394A5
Authority
JP
Japan
Prior art keywords
mlk4
diagnostic method
vitro diagnostic
gene
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013514792A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013528394A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2010/052684 external-priority patent/WO2011158061A1/en
Publication of JP2013528394A publication Critical patent/JP2013528394A/ja
Publication of JP2013528394A5 publication Critical patent/JP2013528394A5/ja
Pending legal-status Critical Current

Links

JP2013514792A 2010-06-15 2010-06-15 Ｍｌｋ４遺伝子、新規の癌診断および予後マーカー Pending JP2013528394A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2010/052684 WO2011158061A1 (en) 2010-06-15 2010-06-15 Mlk4 gene, a new diagnostic and prognostic marker in cancers

Publications (2)

Publication Number Publication Date
JP2013528394A JP2013528394A (ja) 2013-07-11
JP2013528394A5 true JP2013528394A5 (https=) 2013-08-22

Family

ID=43086697

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013514792A Pending JP2013528394A (ja) 2010-06-15 2010-06-15 Ｍｌｋ４遺伝子、新規の癌診断および予後マーカー

Country Status (6)

Country Link
US (1) US9127319B2 (https=)
EP (1) EP2582837A1 (https=)
JP (1) JP2013528394A (https=)
AU (1) AU2010355523B2 (https=)
CA (1) CA2804335A1 (https=)
WO (1) WO2011158061A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
CN113201073A (zh) * 2012-11-21 2021-08-03 詹森生物科技公司 双特异性EGFR/c-Met抗体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861239B1 (en) * 1999-09-20 2005-03-01 New York University Genes and polynucleotides associated with ultraviolet radiation-mediated skin damage and uses thereof
US20070037150A1 (en) * 2003-02-21 2007-02-15 The Johns Hopkins University Tyrosine kinome
WO2005095631A2 (en) * 2004-03-02 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with mixed lineage kinase 4 alpha (mlk4 alpha)
WO2005095637A1 (en) * 2004-03-02 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with mixed lineage kinase 4 beta (mlk4 beta)
ES2426814T3 (es) 2007-03-13 2013-10-25 Amgen Inc. Mutaciones de K-ras y B-raf y terapia con anticuerpos anti-EGFr

Similar Documents

Publication Publication Date Title
Ku et al. Towards precision oncology in advanced prostate cancer
Sun et al. Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients
Pao et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
Zenner et al. Genotype correlates with clinical severity in PIK3CA-associated lymphatic malformations
Lovly et al. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials
Kaira et al. Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis
Collisson et al. What are we learning from the cancer genome?
Okines et al. Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials
Vavalà et al. Precision medicine in age-specific non-small-cell-lung-cancer patients: Integrating biomolecular results into clinical practice—A new approach to improve personalized translational research
HRP20140360T4 (hr) K-ras mutacije i terapija anti-egfr antitijelom
Lee et al. The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors
Kim et al. Expression status of wild-type HSP110 correlates with HSP110 T17 deletion size and patient prognosis in microsatellite-unstable colorectal cancer
CN105705658A (zh) 随时间检测疾病中的突变
Tignanelli et al. KRAS and PIK3CA mutation frequencies in patient-derived xenograft models of pancreatic and colorectal cancer are reflective of patient tumors and stable across passages
Ye et al. Intra-tumoral heterogeneity of HER2, FGFR2, cMET and ATM in gastric cancer: optimizing personalized healthcare through innovative pathological and statistical analysis
Kneuertz et al. Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma
Bruckman et al. Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma
Gabriel et al. Assessing the impact of circulating tumor DNA (ctDNA) in patients with colorectal cancer: separating fact from fiction
Wang et al. Molecular subtyping in colorectal cancer: A bridge to personalized therapy
Wei et al. Circulating tumor DNA measurement provides reliable mutation detection in mice with human lung cancer xenografts
Huang et al. High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study
EP2687609A3 (en) Method for treating solid tumor
Fialka et al. CPA6, FMO2, LGI1, SIAT1 and TNC are differentially expressed in early-and late-stage oral squamous cell carcinoma–a pilot study
JP2011527575A5 (https=)
WO2017197351A1 (en) Methods for identifying clonal mutations and treating cancer